Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden

Vaccine

Volumn 36, Issue 15, 2018, Pages 1917-1920

  Herweijer, Eva ^a   Ploner, Alexander ^a   Sparén, Pär ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Condyloma; HPV; Population level; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; SEX RATIO; SWEDEN; VACCINATION COVERAGE; YOUNG ADULT; COHORT ANALYSIS; HEALTH SURVEY; IMMUNOLOGY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; TIME FACTOR; VACCINATION;

ADOLESCENT; ADULT; COHORT STUDIES; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INCIDENCE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; SWEDEN; TIME FACTORS; VACCINATION; VACCINATION COVERAGE; YOUNG ADULT;

EID: 85042847297     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.02.097     Document Type: Article

References (12)

1. Group TFIS, Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 196:10 (2007), 1438–1446.
2. Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis [Internet]. [Cited 2015 Mar 10]; Available from: < http://www.sciencedirect.com/science/article/pii/S1473309914710734>.
3. Garland, S.M., Steben, M., Sings, H.L., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199:6 (2009), 805–814.
4. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346 (Apr18 1): f2032–f2032.
5. Baandrup, L., Blomberg, M., Dehlendorff, C., Sand, C., Andersen, K.K., Kjaer, S.K., Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 40:2 (2013), 130–135.
6. Leval, A., Herweijer, E., Arnheim-Dahlström, L., et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 206:6 (2012), 860–866.
7. Muggeo, V.M.R., Estimating regression models with unknown break-points. Stat Med 22:19 (2003), 3055–3071.
8. Swedish National Quality Register for Cervical Cancer Prevention, Prevention of Cervical Cancer in Sweden: Annual Report 2014. 2014, Swedish National Quality Register for Cervical Cancer Prevention, Stockholm, Sweden.
9. Folkhälsomyndigheten. Statistik för HPV-vaccinationer – andel vaccinerade flickor till och med 16-12-31 [Internet] [Cited 2016 Apr 26]. Available from: < https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-hpv-vaccinationer/>.
10. Weinberg, G.A., Szilagyi, P.G., Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201:11 (2010), 1607–1610.
11. Blomberg, M., Dehlendorff, C., Munk, C., Kjaer, S.K., Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 57:7 (2013), 929–934.
12. Leval, A., Herweijer, E., Ploner, A., et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 105:7 (2013), 469–474.